Villaris shareholders to receive upfront payment of $70 million, with potential for up to $1.36 billion in additional milestone payments
– Pre-clinical data for auremolimab demonstrate high potency, selectivity and efficacy in vitiligo
– Acquisition will complement Incyte’s existing Inflammation and AutoImmunity portfolio with potential applications for auremolimab beyond Dermatology
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.